GLAXOSMITHKLINE PLC Form 6-K April 12, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 12 April 2019

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company') Transaction notification

- 1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms E Walmsley Chief Executive Officer b) Position/status Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 Acquisition of Ordinary Shares following the
- b) Nature of the transaction

Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan. Price(s) Volume(s) £15.7582 23 n/a (single transaction)

c) Price(s) and volume(s)

Aggregated information

d) Aggregated volume Price

a) Name

e) Date of the transaction	2019-04-11
f) Place of the transaction	London Stock Exchange (XLON)

- 1. Details of PDMR/person closely associated with them ('PCA')
 - Mr R G Connor
- b) Position/status President, Global Vaccines Initial notification/
- c) amendment Initial notification
- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

a) b)	Name LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793	
0)	Details of the transaction(s): section to		
3.	instrument; (ii) each type of transaction place where transaction(s) has been con	; (iii) each dat	•••
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')	
		Acquisition o	of Ordinary
		Shares follow	ving the
		re-investment	t of dividends
b)	Nature of the transaction	paid to sharel	nolders on 11
		April 2019, o	n shares held
		through the C	Company's Share
		Reward Plan.	
c)	Drice(a) and volume(a)	Price(s)	Volume(s)
C)	Price(s) and volume(s)	£15.7582	77
		n/a (single tra	ansaction)
	Aggregated information		

d) Aggregated volume Price

e)	Date of the transaction	2019-04-11
£	Place of the transaction	London Stock Exchange
t)		(XLON)

1.	Details of PDMR/	person closely	associated v	with them ('PCA')

a) Name	Mr S Dingemans
---------	----------------

- b) Position/status Executive Director
 c) Initial notification/ amendment Initial notification
 Initial notification
- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of
- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

		Ordinary snares of 25 pence
a)	Description of the financial instrument	each ('Ordinary Shares')
		ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.

c) Price(s) and volume(s)

Price(s) Volume(s) £15.7582 29 n/a (single transaction)

- Aggregated information
- d) Aggregated volume Price

e)	Date of the transaction	2019-04-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associ	ated with then	n ('PCA')
a)	Name	Mr N Hirons	
b)	Position/status	SVP, Global	Ethics &
0)	r osition/status	Compliance	
c)	Initial notification/ amendment	Initial notific	ation
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	-	cipant, auction
a)	Name	GlaxoSmithk	Kline plc
b)	LEI	5493000HZT	VUYLO1D793
,	Details of the transaction(s): section to	be repeated fo	r (i) each type of
3.	instrument; (ii) each type of transaction		
	place where transaction(s) has been con	ducted	
a)	Description of the financial instrument	Ordinary sha each ('Ordina ISIN: GB000	•
b)	Nature of the transaction	paid to share April 2019, o through the C Reward Plan	ving the t of dividends holders on 11 on shares held Company's Share
c)	Price(s) and volume(s)	Price(s) £15.7582	Volume(s) 14
d)	Aggregated information	n/a (single tra	ansaction)

2019-04-11

(XLON)

London Stock Exchange

Aggregated volume Price

e) Date of the transaction

f)

Place of the transaction

		· · · ·
1.	Details of PDMR/person closely associ	ated with them $('PCA')$
	Name	Ms S Jackson
a)	Indille	
		SVP, Global
b)	Position/status	Communications and CEO
		Office
	Initial notification/	T 1 1 1 1
c)	amendment	Initial notification
	Details of the issuer, emission allowand	a market participant auction
2.		
	platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction(s): section to	be repeated for (i) each type of
3.	instrument; (ii) each type of transaction	; (iii) each date; and (iv) each
	place where transaction(s) has been con	ducted
		Ordinary shares of 25 pence
		each ('Ordinary Shares')
a)	Description of the financial instrument	ISIN: GB0009252882
		ISHA. OD0007232002
		Acquisition of Ordinary
		Shares following the
		re-investment of dividends
b)	Nature of the transaction	paid to shareholders on 11
		April 2019, on shares held
		through the Company's Share
		Reward Plan.
c)	Price(s) and volume(s)	
		£15.7582 71
	Aggregated information	
		n/a (single transaction)
d)	Aggregated volume	
	Price	
e)	Date of the transaction	2019-04-11
2)	Place of the transaction	London Stock Exchange
f)		-
		(XLON)

- 1. Details of PDMR/person closely associated with them ('PCA') Name Mr D Jackson a) PCA of Ms S Jackson (SVP, b) Position/status Global Communications and CEO Office) Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends b) Nature of the transaction paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan. Price(s) Volume(s) c) Price(s) and volume(s) £15.7582 23
 - d) Aggregated volume Price

Aggregated information

e)	Date of the transaction	2019-04-11
Ð	Place of the transaction	London Stock Exchange
1)		(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name
- b) Position/status
- c) Initial notification/ amendment

Mr L Miels President, Global Pharmaceuticals

n/a (single transaction)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

2.	Details of the issuer, emission allowand platform, auctioneer or auction monitor	•	cipant, auction
a)	Name	GlaxoSmithK	line plc
b)	LEI		VUYLO1D793
	Details of the transaction(s): section to		
3.	instrument; (ii) each type of transaction	; (iii) each date	
	place where transaction(s) has been cor		6.05
		•	res of 25 pence
a)	Description of the financial instrument	each ('Ordina	•
	*	ISIN: GB000	9252882
		A aquisition o	f Ordinamy
		Acquisition o	•
		Shares follow	e
		re-investment	
b)	Nature of the transaction	paid to shareh	
		April 2019, o	n shares held
		through the C	Company's Share
		Reward Plan.	
	Drive (a) and volume(a)	Price(s)	Volume(s)
c)	Price(s) and volume(s)	£15.7582	4
		n/a (single tra	unsaction)
	Aggregated information		

- d) Aggregated volume Price
- e) Date of the transaction
- f) Place of the transaction

2019-04-11 London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr D S Redfern b) Position/status Chief Strategy Officer Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

b) Nature of the transaction	April 2019, on shares held through the Company's Share
c) Price(s) and volume(s)	Reward Plan. Price(s) Volume(s) £15.7582 87 n/a (single transaction)
Aggregated information d) Aggregated volume Price	
e) Date of the transactionf)	2019-04-11 London Stock Exchange (XLON)

1.	Details of PDMR/	person closely	associated	with them	('PCA')

Name	Mr R Simard		
Position/status	President, Pharma Supply		
	Chain		
Initial notification/	Initial notification		
amendment	initial notification		
Details of the issuer, emission allowance market participant, auction			
platform, auctioneer or auction monitor			
Name	GlaxoSmithKline plc		
LEI	5493000HZTVUYLO1D793		
Details of the transaction(s): section to	be repeated for (i) each type of		
instrument; (ii) each type of transaction; (iii) each date; and (iv) each			
place where transaction(s) has been conducted			
	Ordinary shares of 25 pence		
Description of the financial instrument	each ('Ordinary Shares')		
	ISIN: GB0009252882		
	Position/status Initial notification/ amendment Details of the issuer, emission allowand platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to instrument; (ii) each type of transaction place where transaction(s) has been cor		

	Acquisition of Ordinary		
	Shares following the		
	re-investment of dividends		
b) Nature of the transaction	paid to shareholders on 11		
	April 2019, on shares held		
	through the Company's Share		
	Reward Plan.		
c) Price(s) and volume(s)	Price(s) Volume(s)		
c) Flice(s) and volume(s)	£15.7582 23		
d) Aggregated information	n/a (single transaction)		

Aggregated volume Price

- e) Date of the transaction
- f) Place of the transaction

2019-04-11 London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Ms C Thomas		
b)	Position/status	SVP, Human Resources		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor			
a)	Name	GlaxoSmithKline plc		
b)	LEI	5493000HZTVUYLO1D793		
- /	Details of the transaction(s): section to			
3.	instrument; (ii) each type of transaction			
с.	place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')		
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.		
c)	Price(s) and volume(s)	Price(s)Volume(s)£15.758287n/a (single transaction)		
	Aggregated information			
d)	Aggregated volume			

- Aggre Price
- e) Date of the transaction

f) Place of the transaction

2019-04-11 London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr P C Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
	Name	GlaxoSmithKline plc	
a) h)	LEI	5493000HZTVUYLO1D793	
b)			
2	Details of the transaction(s): section to		
3.	instrument; (ii) each type of transaction		
	place where transaction(s) has been con		
		Ordinary shares of 25 pence	
a)	Description of the financial instrument	each ('Ordinary Shares')	
	1.	ISIN: GB0009252882	
,	Nature of the transaction Price(s) and volume(s)	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan. Price(s) Volume(s) £15.7582 50 n/a (single transaction)	
	Aggregated information		
d)	Aggregated volume Price		

2019-04-11
London Stock Exchange
(XLON)

1.	Details of PDMR/person clos	ely associated with them ('PCA')
----	-----------------------------	----------------------------	--------

- a) Name Mrs V A Whyte
- b) Position/status
 c) Initial notification/ amendment
 c) Company Secretary Initial notification/ Initial notification
- 2.

	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithK	line nlc
,	LEI		VUYLO1D793
0)			
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument: (ii) each type of transactions (iii) each date and (iv)		
5.	······································		
	each place where transaction(s) has been conducted Ordinary shares of 25 per		
		•	-
a)	Description of thefinancial instrument	each ('Ordinai	•
	-	ISIN: GB0009	9252882
		A	
		Acquisition of	•
		Shares follow	•
1 \		re-investment of dividends	
b)	Nature of the transaction	paid to shareh	
		April 2019, or	
			ompany's Share
		Reward Plan.	
		Price(s)	Volume(s)
c)	Price(s) and volume(s)	£15.7582	63
		n/a (single tra	nsaction)
	Aggregated information		
d)			
(1)	Aggregated volume		
	Price		

e) Date of the transaction

f) Place of the transaction

2019-04-11 London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant) Date: April 12, 2019

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc